Seed VC · Stockholm, Sweden
Nicoya is a Canadian biotechnology company specializing in the development of innovative analytical instruments for life sciences research. Founded in 2012 and headquartered in Kitchener, Ontario, Nicoya is best known for its surface plasmon resonance (SPR) technology, which enables label-free biomolecular interaction analysis. The company’s flagship products, such as OpenSPR and Alto, are widely used by academic and pharmaceutical researchers for drug discovery and protein characterization. Nicoya has received recognition for its technological advancements and rapid growth, including awards for innovation and entrepreneurship. The company has expanded its presence internationally and continues to invest in research and development to advance accessible and affordable biosensor solutions.
We never publish partner emails directly — score your deck to unlock contacts for the firms ranked as best-fit.
Nicoya writes first institutional checks where the founder + early product matter more than traction. The seed market is the most dispersed segment of venture; matching to thesis (sector, stage, geography) is where most cold outreach succeeds or fails. Claude Fundraiser tracks Nicoya alongside 45,000+ other active investors, ranked weekly by recent-deal momentum, sector concentration, and partner activity.
Drop your pitch. Claude scores it on the 8 dimensions VCs read for and ranks the 45,000+ active investors in the database by fit. Nicoya is one of them — and we'll tell you exactly where they sit in your top 100.